98%
921
2 minutes
20
Introduction: Subjective cognitive decline (SCD) has been associated with elevated amyloid levels and increased risk of future cognitive decline, as well as modifiable variables, including depression, anxiety, and physical inactivity. Participants generally endorse greater and earlier concerns than their close family and friends (study partners [SPs]), which may reflect subtle changes at the earliest stages of disease among participants with underlying neurodegenerative processes. However, many individuals with subjective concerns are not at risk of Alzheimer's disease (AD) pathology, suggesting that additional factors, such as lifestyle habits, may be contributory.
Methods: We examined the relation between SCD, amyloid status, lifestyle habits (exercise, sleep), mood/anxiety, and demographic variables among 4481 cognitively unimpaired older adults who are being screened for a multi-site secondary prevention trial (A4 screen data; mean ±SD: age = 71.3 ±4.7, education = 16.6 ±2.8, 59% women, 96% non-Hispanic or Latino, 92% White].
Results: On the Cognitive Function Index (CFI) participants endorsed higher concerns compared to SPs. Participant concerns were associated with older age, positive amyloid status, worse mood/anxiety, lower education, and lower exercise, whereas SP concerns were associated with older participant age, male gender of participant, positive amyloid status of participant, and worse participant-reported mood/anxiety.
Discussion: Findings suggest that modifiable/lifestyle factors (e.g., exercise, education) may be associated with participant concerns among cognitively unimpaired individuals and highlight the importance of further examining how modifiable factors impact participant- and SP-reported concerns, which may inform trial recruitment and clinical interventions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248212 | PMC |
http://dx.doi.org/10.1002/dad2.12435 | DOI Listing |
JAMA Netw Open
September 2025
School of Medicine and Public Health, University of Wisconsin-Madison, Madison.
Importance: It is unclear whether the duration of amyloid-β (Aβ) pathology is associated with neurodegeneration and whether this depends on the presence of tau.
Objective: To examine the association of longitudinal atrophy with Aβ positron emission tomography (PET)-positivity (Aβ+) and the estimated duration of Aβ+ (Aβ+ duration), controlling for tau-positivity.
Design, Setting, And Participants: Data for this longitudinal cohort study were drawn from the Wisconsin Registry for Alzheimer Prevention and the Wisconsin Alzheimer Disease Research Center Clinical Core Study.
Alzheimers Dement
September 2025
Research Service, VA San Diego Healthcare System, San Diego, California, USA.
Introduction: Among individuals who are amyloid biomarker-positive or apolipoprotein E (APOE) ε4 carriers, arterial stiffness reflected by higher pulse wave velocity (PWV) has been associated with lower cognition cross-sectionally. Less is known about longitudinal associations.
Methods: The sample included 152 older adults without dementia.
J Alzheimers Dis Rep
September 2025
Communication Sciences and Disorders, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Background: The presence of the apolipoprotein E4 () allele and periodontal disease are independently correlated with higher levels of amyloid-β and inflammation in the brain, worse cognition, and Alzheimer's disease.
Objective: To assess whether the presence of the allele modifies the relationship between IgG antibodies against periodontal microorganisms and cognitive function in older adults participating in the NHANES III study.
Methods: This cross-sectional analysis was conducted among participants of the third National Health and Nutrition Examination Survey (NHANES III) (1988 to 1994), aged 60 years and older, with measurements of IgG antibodies against 19 periodontal microorganisms and alleles (N = 1644).
Wien Klin Wochenschr
September 2025
Department of Neurology, Medical University of Vienna, Vienna, Austria.
Background: Disease-modifying therapies with amyloid-antibodies will soon be available for patients with early Alzheimer's disease, which necessitates diagnostic and therapeutic resources in hospital and outpatient settings.
Methods: The Austrian Alzheimer Society developed an online questionnaire to survey Austrian hospital-based departments of neurology and psychiatry regarding resources for amyloid-antibody therapies.
Results: Between May and October 2023, 30 out of 41 neurology (73%) and 12 out of 33 psychiatry departments (36%) responded.
Arch Physiol Biochem
September 2025
Department of GCP Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Background: Post-stroke cognitive impairment (PSCI), a common complication following stroke, significantly impacts patients' quality of life and prognosis. Research indicates that neuroregulation and protein metabolic disorders play crucial roles in the development of PSCI.
Purpose: This study aimed to evaluate the reliability of the Regional Meningoarterial Score (rLMC) in determining collateral circulation status in acute ischaemic stroke patients.